On announcing the team of Commissioner designates he wanted to include in his Commission team for 2014-19, Juncker included a controversial proposal to shift the responsibilities for pharmaceutical regulation and medical devices away from the Directorate General for Health (DG SANCO), and to place these roles into the Directorate General for Enterprise and Industry (DG ENTR).
EAHP joined with European associations representing community pharmacists (PGEU), doctors (CPME, UEMS) and dozens of patient and consumer organisations in calling the proposals misguided and seeking reversal of the suggestion. The 28 organisations believe that the public health focus and imperative in relation to pharmaceutical regulation and oversight could be lost, with DG Enterprise’s prime responsibilities being to commercial interests rather than public health.
The campaign to reverse Juncker’s proposal is led by the European Public Health Alliance (EPHA). More information here.
In the meantime, as previously reported in the EU Monitor, former Lithuanian Health Minister and surgeon Vytenis Andriukaitis is proposed to take the DG SANCO health portfolio. Meanwhile, former Deputy Prime Minister of Poland Elzbieta Bienkowska is poised to take the DG Enterprise portfolio, with expanded responsibilities for pharmaceutical legislation and medical device regulation.
Dates for hearings between the designate Commissioners and the European Parliament have now been scheduled, with Mr Andriukaitis appearing before the Parliament’s Health Committee on 30th September and Ms Bienkowska meeting with the Industry and Internal Market Committees on 2nd October.
EAHP and partners will brief MEPs on key topics of health concern in advance of the hearings in order that relevant issues tot he European hospital pharmacy profession may be raised and highlighted.
This information was originally published on the EAHP website and can be found here